Lexaria Bioscience Corp. (LEXX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 08-31. Amounts in USD.

Revenue Annual

0 250K 500K 750K FY16: 40.7K FY17: 63.6K FY18: 433.3K FY19: 222.6K FY20: 314.8K FY21: 722.7K FY22: 255.4K FY23: 226.2K FY24: 464.3K FY25: 705.9K FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

-250K 0 250K 500K 750K FY14: 0 FY15: -15.2K FY16: -4.9K FY17: 33.9K FY18: 408.1K FY19: 199.7K FY20: 215.4K FY21: 547.4K FY22: 183.6K FY23: 194.7K FY24: 459.5K FY25: 703.2K FY15 FY17 FY19 FY21 FY23 FY25

Operating Income Annual

-15M -10M -5M 0 5M 10M 15M FY14: -1.6M FY15: -2M FY16: -1.3M FY21: -5.7M FY22: -6.6M FY23: -6.5M FY24: -5.8M FY25: -11.9M FY14 FY15 FY16 FY21 FY22 FY23 FY24 FY25

Net Income Annual

-15M -10M -5M 0 5M 10M 15M FY14: -1.6M FY15: -2M FY16: -1.3M FY17: -1.9M FY18: -6.6M FY19: -4.2M FY20: -4.1M FY21: -4M FY22: -7.3M FY23: -6.7M FY24: -5.8M FY25: -11.9M FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 60K 120K 180K FY16: 45.6K FY17: 29.8K FY18: 25.2K FY19: 22.9K FY20: 99.4K FY21: 175.3K FY22: 71.8K FY23: 31.5K FY24: 4.8K FY25: 2.7K FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-12M -8M -4M 0 4M 8M 12M FY14: -515.8K FY15: -1.5M FY16: -660.9K FY17: -1.5M FY18: -2.5M FY19: -3M FY20: -2.6M FY21: -4M FY22: -4.9M FY23: -5.9M FY24: -5M FY25: -10.5M FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-12M -8M -4M 0 4M 8M 12M FY15: -1.5M FY16: -664K FY17: -1.5M FY19: -3.7M FY20: -2.6M FY22: -4.9M FY23: -5.9M FY24: -5M FY25: -10.5M FY15 FY16 FY17 FY19 FY20 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 7M 14M 21M FY23: 6.6M FY24: 12.4M FY25: 18M FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.50 -1.00 -0.50 0.00 0.50 1.00 1.50 Q3 '11: -0.02 Q4 '11: -0.04 Q1 '12: -0.04 Q2 '12: -0.04 Q3 '12: -0.04 Q4 '12: -0.02 Q1 '13: -0.02 Q2 '13: -0.02 Q3 '13: -0.01 Q4 '13: -0.01 Q1 '16: -0.04 Q2 '16: -0.04 Q3 '16: -0.04 Q4 '16: -0.04 Q1 '17: -0.04 Q1 '18: -0.04 Q2 '18: -0.05 Q3 '18: -0.09 Q4 '18: -0.09 Q1 '19: -0.09 Q2 '19: -0.08 Q3 '19: -0.04 Q4 '19: -0.04 Q1 '20: -0.36 Q2 '20: -0.73 Q3 '20: -1.22 Q4 '20: -1.45 Q1 '21: -1.36 Q2 '21: -0.89 Q3 '21: -0.89 Q4 '21: -0.89 Q1 '22: -1.00 Q2 '22: -1.34 Q4 '24: -0.47 Q1 '25: -0.50 Q2 '25: -0.59 Q3 '25: -0.67 Q4 '25: -0.65 Q1 '26: -0.56 Q2 '26: -0.47 Q3 '26: -0.34 Q3 '12 Q1 '16 Q2 '18 Q4 '19 Q2 '21 Q1 '25 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.